| | 156137-99-4 Basic information More.. |
| Product Name: | Rapacuronium | | Synonyms: | Rapacuronium;Org 9487;Raplon;[(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-3-acetyloxy-10,13-dimethyl-2-piperidin-1-yl-16-(1-prop-2-enylpiperidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] propanoate | | CAS: | 156137-99-4 | | MF: | C37H61BrN2O4 | | MW: | 677.81 | | EINECS: | | | Mol File: | 156137-99-4.mol |  |
Use
Rapacuronium bromide was introduced in the US as a parenterally
administered adjunct to general anesthesia during surgical procedures. It is a
new steroidal derivative belonging to the same class as vecuronium bromide.
This 2,16-bispiperidinylandrostane derivative can be synthesized in 3 steps from
the 3-hydroxy-androstan-17-one analog and finally quaternized with allyl
bromide. Rapacuronium bromide is a nondepolarizing neuromuscular blocking
drug with a rapid onset and a short duration of action. With a relatively low
potency (ED90 = 1.15 mg/kg), Rapacuronium is expected to be substituted for
the polarizing succinylcholine with very short duration of action.
- Rapacuronium bromide
-
- US $347.00-1320.00 / mg
- 2024-10-28
- CAS:156137-99-4
- Min. Order:
- Purity:
- Supply Ability: 10g
|
|
156137-99-4
Recommend Suppliers |
|